Pharmaceutical - Endocyte

Filter

Current filters:

Endocyte

Popular Filters

Merck and Endocyte pull CMA for vintafolide and companion imaging component in EU

20-05-2014

US pharma giant Merck & Co and Endocyte have withdrawn their conditional marketing authorization applications…

EndocyteEuropeMerck & CoOncologyPharmaceuticalRegulationResearchvintafolide

Endocyte plummets on decision to stop vintafolide Ph III trial; posts financials

03-05-2014

US pharma giant Merck & Co and partner Endocyte revealed on Friday that the Data Safety Monitoring Board…

EndocyteFinancialMerck & CoOncologyPharmaceuticalResearchvintafolide

EMA/CHMP backs approval of Merck ovarian cancer drug Vynfinit and companion diagnostics

21-03-2014

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended…

EndocyteEuropeFolcepriMerck & CoNeocepriOncologyPharmaceuticalRegulationVynfinit

Former OSI CEO Colin Goddard joins Endocyte board of directors

Former OSI CEO Colin Goddard joins Endocyte board of directors

13-11-2013

US biopharma company Endocyte (Nasdaq: ECYT) has announced that Colin Goddard has joined its board of…

BoardroomEndocyteNorth AmericaPharmaceuticalUSA

New data on Merck and Endocyte’s vintafolide in ovarian cancer

New data on Merck and Endocyte’s vintafolide in ovarian cancer

15-10-2013

Merck & Co and partner Endocyte today announced the on-line publication of results from the randomized…

EndocyteMerck & CoOncologyPharmaceuticalResearchvintafolide

Merck & Co in potential $1 billion deal for cancer drug candidate vintafolide

17-04-2012

US drug giant Merck & Co (NYSE: MRK) has entered into an agreement to develop and commercialize Endocyte's…

BiotechnologyEndocyteetarfolatideLicensingMerck & CoOncologyPharmaceuticalvintafolide

Back to top